It is currently not known whether breast tumors with low-positive (1–9%) or intermediate-positive (10–50%) ER expression are comparable to TNBC in terms of immune characteristics that are relevant for ICB response and whether these patients are therefore more likely to respond to ICB. This evidence concerns the gene ESR1 and breast neoplasm.